Resveratrol: A Potential Anti- Remodeling Agent in Heart Failure, From Bench to Bedside (RES-HF)
Resveratrol: A Potential Anti- Remodeling Agent in Heart Failure, From Bench to Bedside (RES-HF)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Wendy Janz, RN
- Phone Number: 204-237-2793
- Email: wjanz@exchange.mb.ca
Study Locations
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R2H 2A6
- Recruiting
- St. Boniface General Hospital
-
Contact:
- Wendy Janz, RN
- Phone Number: 204-237-2793
- Email: wjanz@hsc.mb.ca
-
Sub-Investigator:
- Amrit Malik, MD
-
Principal Investigator:
- Shelley Zieroth, MD
-
Sub-Investigator:
- Thomas Netticadan, Ph. D.
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects (between 18-90 years of age) with cardiomyopathy, Heart Failure with reduced ejection fraction (HFrEF defined as Left Ventricular Ejection Fraction (LVEF) ≤40%, based on most recent assessment)
- New York Heart Association (NYHA) Functional class II-III (mild-moderate heart failure symptoms)
- On optimal medical management for 6 months as per standard care
Exclusion Criteria:
- Severe valvular cardiomyopathy
- No surgical intervention planned or in past 6 months
- Subjects on \diltiazem (or any other calcium channel blocker)
- Patients with a history of serious hypoglycemia requiring hospitalization or hyperglycemic emergencies requiring hospitalization in the past 6 months
- Subjects on anticoagulants, Coumadin, dabigatran
- Subjects on HIV protease inhibitor (saquinivir), immunosupressants (cyclosporine, tacrolimus)
- Subjects on terfenadine, midazolam, and triazolam
- Subjects on sildenafil or any other drugs used to treat erectile dysfunction
- • Chronic renal failure (defined as estimated glomerular filtration rate (eGFR) ≤30 mL/min per 1.73m2)
- Known liver cirrhosis
- • Other significant comorbidity e.g. cancer affecting ability to complete study
- Pregnant or lactating women
- Subjects on hormone replacement therapy
- Subjects on estrogen containing birth control
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Resveratrol
500 mg (1 capsule BID) of resveratrol for 12 months
|
Patients will receive one uncoated immediate-release caplets containing 500 mg resveratrol, twice daily for the 12 month intervention period
Other Names:
|
|
Placebo Comparator: Placebo
500 mg (1 capsule BID) of placebo for 12 months.
|
Patients will receive one uncoated caplet containing placebo, twice daily for the 12 month intervention period
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Quality of life
Time Frame: 12 months
|
Measured by Minnesota living with heart failure score
|
12 months
|
|
Cardiac Function
Time Frame: 12 months
|
Echocardiography
|
12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Oxidative Stress
Time Frame: 12 Months
|
Measurement of oxidative stress using the Oxiselect TBARS Assay.
|
12 Months
|
|
Total Antioxidant Status
Time Frame: 12 Months
|
Measurement of total antioxidant status (TAS) level.
|
12 Months
|
|
Inflammatory Marker Measurements
Time Frame: 12 Months
|
Inflammatory markers will be measured by plasma levels of interleukin 6 (IL6) and tumor necrosis factor (TNF).
|
12 Months
|
|
Nitric Oxide Determination
Time Frame: 12 Months
|
Total nitric oxide levels will be measured.
|
12 Months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Shelley Zieroth, MD, St. Boniface Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Genetic Diseases, Inborn
- Cardiomegaly
- Laminopathies
- Heart Failure
- Cardiomyopathies
- Cardiomyopathy, Dilated
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Platelet Aggregation Inhibitors
- Protective Agents
- Antioxidants
- Resveratrol
Other Study ID Numbers
Other Study ID Numbers
- CTA/2012/0002
- RRC/2011/1169 (Other Identifier: St. Boniface Hospital)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.